Equities Research Analysts’ Upgrades for January, 22nd (AA, AGR, AHEXY, AHH, AIMC, ALRM, AMED, ANDV, ANGO, ARCB)

Equities Research Analysts’ upgrades for Monday, January 22nd:

Alcoa (NYSE:AA) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $61.00 target price on the stock. According to Zacks, “Alcoa is a global industry leader in bauxite, alumina and aluminum products. “

Avangrid (NYSE:AGR) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Avangrid, Inc. is an energy and utility company. The company operates regulated utilities, electricity generation and natural gas storage primarily in the United States. Avangrid, Inc. is based in New Gloucester, United States. “

Adecco Group (OTCMKTS:AHEXY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $46.00 price target on the stock. According to Zacks, “Adecco Group offers a wide variety of services that connects colleagues with clients every day. The services offered fall into the broad categories of temporary staffing, permanent placement, outsourcing, consulting and outplacement. It also provides services in various business lines such as information technology, finance and legal, engineering and technical, medical and science, human capital solutions, sales, marketing and events. Adecco S.A. is headquartered in Glattbrugg, Switzerland. “

Armada Hoffler Properties (NYSE:AHH) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Armada Hoffler Properties, Inc. is a real estate investment trust. It is engaged in developing, building, owning and managing office, retail and multifamily properties primarily in the United States. Its properties are situated in Virginia and North Carolina. Armada Hoffler Properties, Inc. is based in Virginia Beach, United States. “

Altra Industrial Motion (NASDAQ:AIMC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $60.00 price target on the stock. According to Zacks, “In the six months, Altra Industrial's shares have outperformed the industry. We believe that the company is poised to benefit from its solid product portfolio, exposure to diversified end markets, wide customer base and inorganic growth initiatives. For instance, the Stromag acquisition is predicted to be earnings accretive in 2017. Also, the company has been progressing well on its restructuring and cost-saving strategies. For 2017 (results not yet released), the company increased its revenue guidance to $860-$870 million from the previous projection of $850-$865 million. Non-GAAP earnings are anticipated to be within $2.00-$2.06 per share, up from the earlier forecast of $1.95-$2.05. Earnings estimates for 2018 have improved in the last 60 days.”

AlarmCom (NASDAQ:ALRM) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $45.00 target price on the stock. According to Zacks, “Alarm.com Holdings, Inc. offers interactive security solutions for home and business owners. The Company offers security systems which include image sensor, crash and smash protection, web control, mobile access and video monitoring. Alarm.com Holdings, Inc. is based in VIENNA, United States. “

Amedisys (NASDAQ:AMED) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $62.00 price target on the stock. According to Zacks, “Over the past year, Amedisys has been trading above the broader industry. The company is currently exploring new opportunities in both Home Health and Hospice. At the Home Health division, the company witnessed a decline in Medicare revenues, while there was an improvement in non-Medicare revenues. At the Hospice division, the company registered strong growth across all segments. A favorable demographic trend and strategic acquisitions bode well for the company. On the flip side, escalating operating expenses and declining gross margin continue to raise concerns. Also, an intense competitive landscape and regulatory concerns continue to pose challenges in the home health and hospice industry.”

Andeavor (NYSE:ANDV) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $133.00 target price on the stock. According to Zacks, “Andeavor Corp engages in the refining and marketing of petroleum products. The company’s operating segments consists of Refining, Logistics and Marketing. Refining segment refines crude oil and other feed stocks into transportation fuels, such as gasoline and gasoline blend stocks, jet fuel and diesel fuel, as well as other products, including heavy fuel oils, liquefied petroleum gas and petroleum coke for sale in bulk markets. Logistics segment includes crude oil and natural gas gathering assets, natural gas and natural gas liquid processing assets and crude oil and refined products terminalling, transportation and storage assets. Marketing segment sells transportation fuels through branded and unbranded channels. Its brand portfolio includes ARCO, Shell, Exxon, Mobil, USA Gasoline, Rebel and Tesoro. Andeavor Corp, formerly known as Tesoro Corporation, is headquartered in San Antonio, Texas. “

AngioDynamics (NASDAQ:ANGO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $19.00 price target on the stock. According to Zacks, “Despite trading below the broader industry in the last year, market’s solid response to Solero platform, especially within the Microwave Ablation space, is likely to boost AngioDynamics. The company has been offering a broad spectrum of products which has helped widen its commercial opportunities. AngioDynamics is also a leading player in the thrombolytic catheters space. The company boasts highly unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio. On the flipside, the company’s Peripheral Vascular business segment witnessed a downside scenario. The company also had a high outstanding debt level at the end of the second quarter. AngioDynamics’ higher debts impose certain operating and financial restrictions which limit the company’s execution of the company’s core business strategies. The company also recalled the Acculis Microwave Tissue Ablation System recently.”

ArcBest (NASDAQ:ARCB) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $44.00 price target on the stock. According to Zacks, “ArcBest Corporation provides freight transportation services and solutions. The company’s Freight Transportation segment offers transportation of general commodities; motor carrier freight transportation services; business-to-business air transportation services; ocean transport services; global customizable supply chain solutions and integrated warehousing services. Its Premium Logistics & Expedited Freight Services segment provides expedited freight transportation services to commercial and government customers; premium logistics services; and domestic and international freight transportation with air, ocean, and ground service. ArcBest Corporation, formerly known as Arkansas Best Corporation, is headquartered in Fort Smith, Arkansas. “

Amtech Systems (NASDAQ:ASYS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “AMTECH SYSTEMS, INC. is engaged in the manufacture of several items of capital equipment, one of which is patented, used by customers in the manufacture of semiconductors. Co. has recently obtained a U.S. patent on technology on which it expects to base a proposed new photo chemical vapor deposition (CVD) product for use in semiconductor manufacturing facilities. The Company has engaged the University of California, Santa Cruz, to conduct a study to determine the feasibility of such a product. “

Atlas Copco (OTCMKTS:ATLKY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $53.00 price target on the stock. According to Zacks, “ATLAS COPCO is a world leading provider of industrial productivity solutions. The products and services range from compressed air and gas equipment, generators, construction and mining equipment, industrial tools and assembly systems, to related aftermarket and rental. In close cooperation with customers and business partners, and with 135 years of experience, Atlas Copco innovates for superior productivity. Headquartered in Stockholm, Sweden, the Group’s global reach spans more than 160 markets. “

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

Barclays (NYSE:BCS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Barclays' shares on NYSE have underperformed the industry over the past six months. Also, the company has surpassed the Zacks Consensus Estimate for earnings in only one of the trailing four quarters. It has been facing pressure on revenues owing to weak capital market performance, low interest rates and uncertainty related to Brexit. Further, the U.S. tax act will result in a one-time charge of $1.3 billion in the fourth quarter, thereby hurting the bank's profitability in 2017. However, the bank's restructuring and business simplifying efforts have ended successfully and will likely continue to result in decrease in expenses. Also, driven by these efforts, the company is expected to enhance capital deployment activities as profitability improves going forward.”

BioTelemetry (NASDAQ:BEAT) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. BioTelemetry, Inc., formerly known as CardioNet, Inc., is headquartered in Conshohocken, Pennsylvania. “

Diageo (NYSE:DEO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $163.00 target price on the stock. According to Zacks, “Shares of Diageo have outperformed the industry in the past one year, driven by its strong fundamentals, continuous innovation and focus on expansion. Also, the company’s strategic endeavors including growth via acquisitions remain noteworthy. In fact, the buyout of the U.S. fastest-growing premium tequila brand, Casamigos, is expected to boost its market share in the category and is likely to capitalize on the company’s presence in the high-growth international markets. Notably, alcohol stocks are doing well backed by the rising demand for flavored whisky, premium tequilas and spirits. Further the company has been striving toward expanding its presence in emerging regions as well as focus on high-margin products. However, currency fluctuations as well as other macroeconomic factors such as interest rate hikes and increase in fuel and energy costs may also impact the company’s profitability.”

Infosys (NYSE:INFY) was upgraded by analysts at UBS Group AG from a neutral rating to a buy rating.

LifePoint Health (NASDAQ:LPNT) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “LifePoint Health’s stock has underperformed the industry in a year’s time, but its strong Value Score, attractive valuation and upward revision in earnings estimates presents a good investment opportunity. The company’s inorganic growth strategies have aided its overall growth. Disciplined share buyback also provides support to its bottom line. Nevertheless, the company trimmed its 2017 guidance for the second time on a challenging volume environment and weak revenue growth. The company is faced with increasing expenses which has outpaced revenue growth thereby squeezing operating margins. High bad debt is another concern as is declining cash flows.”

Ralph Lauren (NYSE:RL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Ralph Lauren outperformed the industry in the past three months. Second-quarter fiscal 2018 marked the company’s 11th consecutive earnings beat and sales topped estimates after two consecutive misses. However, the company’s North America business continues to suffer due to distribution and brand exits; planned reduction in shipments and promotions to enhance the quality of sales; and lower customer demand. Revenues at the North America segment slumped 16% in the second quarter owing to lower retail and wholesale sales. Additionally, high dependence on outside suppliers poses threats. Nonetheless, the company adjusted its fiscal 2018 guidance to account for the recent positive movements in foreign currency rates, which will aid revenue and operating margins in fiscal 2018. The company remains on track to deliver its goals under its Way Forward Plan, which bodes well. Estimates have been going up ahead of the third-quarter earnings.”

Roper Technologies (NYSE:ROP) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $309.00 price target on the stock. According to Zacks, “Roper shares have outperformed the industry in the past one-year. The company has an optimum mix of highly engineered and niche-oriented products, which help it to gain market share. Moreover, Roper's unique asset light business model not only lowers its dependence on large-scale production equipment but also helps it to generate strong cash flow quickly. This coupled with improving balance sheet is helping it to pursue strategic acquisitions. Successful integration of the acquisitions has contributed meaningfully to the top line and margins. Furthermore, Roper holds a dominant position in most of the markets where it operates.  However, sluggish global macroeconomic conditions and stiff competition remain headwinds.                                                             “

Companhia de Saneamento Basico (NYSE:SBS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “In the last three months, SABESP's American Depository Receipts (ADR) outperformed the industry. Over the long term, we believe that rising Brazilian population will increase demand for water and sewage services. By 2022, the company aims to add nearly one million new water connections and 1.3 million new sewage connections. Also, it has planned investments worth R$13.9 billion for 2017-2021. However, risks arising from governmental interference and dependence on electricity as a source of energy remain issues. Moreover, high debt levels, if unchecked, will inflate the company's financial obligations, posing serious threats to profitability. Earnings estimates on the stock remained stable for 2018 in the last 60 days.”

Total System Services (NYSE:TSS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $93.00 price target on the stock. According to Zacks, “Shares of Total System have outperformed its industry in last year. The company is set to benefit from its robust NetSpend business, while the TransFirst and Cayan acquisition will support its merchant acquiring business. Numerous acquisitions made by the company have contributed to overall growth.  Following a strong performance in the first nine months of the year, the company raised its 2017 earnings guidance, which instills investors' confidence. Total System has strengthened its capital position by reducing debt to its targeted range. Resumption of share buyback is another positive. The stock has seen the Zacks Consensus Estimate for 2018 earnings being revised 1.1% upward over the last 90 days. Nevertheless, exposure to foreign exchange volatility and investment expenses might weigh on the margins in the coming quarters.”

Receive News & Ratings for Alcoa Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcoa Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply